Australia's most trusted
source of pharma news
Thursday, 21 November 2024
Posted 19 November 2024 AM
Doherty Clinical Trials (DCT) has applied to the OGTR to conduct a first-in-human clinical trial using a genetically modified influenza virus to test the efficacy of potential vaccines and therapeutic drugs.
Using gene technology (reverse genetics), the recombinant human influenza virus A and B (including H1N1 and H3N2) will be similar to naturally circulating wild type seasonal influenza viruses.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.